Press releases
- Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
- Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
More ▼
Key statistics
As of last trade Sarepta Therapeutics Inc (AB3A:DUS) traded at 123.24, -16.74% below its 52-week high of 148.02, set on Mar 06, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 123.88 |
---|---|
High | 126.46 |
Low | 121.74 |
Bid | 123.26 |
Offer | 124.38 |
Previous close | 121.50 |
Average volume | 75.10 |
---|---|
Shares outstanding | 87.98m |
Free float | 83.68m |
P/E (TTM) | -- |
Market cap | 11.56bn USD |
EPS (TTM) | -8.03 USD |
Data delayed at least 15 minutes, as of Mar 21 2023 17:31 BST.
More ▼